FarmaKology’s Substack

Share this post

FarmaKology Newsletter - Issue #1

www.farmakology.com

FarmaKology Newsletter - Issue #1

FarmaKology
Mar 27, 2019
Share this post

FarmaKology Newsletter - Issue #1

www.farmakology.com

The FDA has dashed Sanofi's hopes of launching its type I diabetes drug, Zynquista, this year.

News

FDA rejects oral Type I diabetes drug

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Sanofi’s type I diabetes drug, Zynquista (sotagliflozin).

NICE recommend Takeda's lymphoma treatment Adcetris

Britain’s cost effectiveness body has recommended Takeda’s Adcetris (brentuximab vedotin) for adult patients with CD-30 positive advanced cutaneous T-cell lymphoma (CTCL).

Alzheimer’s trial discontinued due to inefficiency

Biogen and Eisai have stopped two global Phase III trials of the Alzheimer's drug aducanumab, after interim analyses indicated that the agent was ineffective and would not meet the primary endpoint.

Bayer and Johnson & Johnson Settle Lawsuits Over Xarelto, a Blood Thinner, for $775 Million

The settlement resolves about 25,000 lawsuits, which claimed the companies failed to warn about deadly bleeding episodes caused by the drug.

Research

Multi-drug approach found to attack resistance in bowel cancer

Digital Intervention Ups Socialization in Children With Autism

Podcasts

Hear from 2019 Guild Pharmacy of the Year finalist, Emerald Plaza Pharmacy owner Jessica Burrey who has a vision to create a health hub to service the community and collaborate with the wider health sector.

Job Opportunities

Advanced Clinical Pharmacist EFL JFK

Clinical Pharmacist - Butterworth Hospital

Pharmacist

Consultant Pharmacist

Share this post

FarmaKology Newsletter - Issue #1

www.farmakology.com
Comments
TopNew

No posts

Ready for more?

© 2023 FarmaKology
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing